KFS
NAVB

Kelly Financial Services’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Kelly Financial Services’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50
Closed -$4 – 818
2023
Q3 		$4 Hold
50
– – ﹤0.01% 764
2023
Q2 		$5 Hold
50
– – ﹤0.01% 723
2023
Q1 		$13 Hold
50
– – ﹤0.01% 699
2022
Q4 		$11 Hold
50
– – ﹤0.01% 687
2022
Q3 		$13 Hold
50
– – ﹤0.01% 698
2022
Q2 		$36 Hold
50
– – ﹤0.01% 677
2022
Q1 		$40 Hold
50
– – ﹤0.01% 669
2021
Q4 		$50 Hold
50
– – ﹤0.01% 674
2021
Q3 		$88 Sell
50
-42
-46% -$71 ﹤0.01% 638
2021
Q2 		$50K Buy
92
+42
+84% +$74 ﹤0.01% 462
2021
Q1 		$101 Hold
50
– – ﹤0.01% 626
2020
Q4 		$108 Hold
50
– – ﹤0.01% 582
2020
Q3 		$135 Hold
50
– – ﹤0.01% 560
2020
Q2 		$197 Hold
50
– – ﹤0.01% 569
2020
Q1 		$38 Hold
50
– – ﹤0.01% 570
2019
Q4 		$63 Hold
50
– – ﹤0.01% 551
2019
Q3 		$35 Hold
50
– – ﹤0.01% 547
2019
Q2 		$32 Hold
50
– – ﹤0.01% 496
2019
Q1 		$138 Buy
+50
New +$147 ﹤0.01% 479

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Kelly Financial Services's NAVB Position: Q4 2023 in Review

Kelly Financial Services sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 50 shares — an estimated $4 sold.

Kelly Financial Services first reported a position in NAVB in Q1 2019 and held it in 19 quarters. The position peaked at $50K in Q2 2021. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Kelly Financial Services reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Kelly Financial Services sold 50 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $4.
  • Kelly Financial Services first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2019 and held it in 19 quarters.
  • Kelly Financial Services's Navidea Biopharmaceuticals Inc. position peaked at $50K in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Kelly Financial Services's 13F filing for Q4 2023, filed 17 Jul 2024.